Metacrine (Metacrine) Net Margin % : 0.00% (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Metacrine Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Metacrine's Net Income for the three months ended in Sep. 2022 was $-5.52 Mil. Metacrine's Revenue for the three months ended in Sep. 2022 was $0.00 Mil. Therefore, Metacrine's net margin for the quarter that ended in Sep. 2022 was 0.00%.

The historical rank and industry rank for Metacrine's Net Margin % or its related term are showing as below:

MTCR's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -157.59
* Ranked among companies with meaningful Net Margin % only.

Metacrine Net Margin % Historical Data

The historical data trend for Metacrine's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metacrine Net Margin % Chart

Metacrine Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Net Margin %

-1,780.76

Metacrine Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Net Margin %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Metacrine's Net Margin %

For the Biotechnology subindustry, Metacrine's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metacrine's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metacrine's Net Margin % distribution charts can be found below:

* The bar in red indicates where Metacrine's Net Margin % falls into.

Metacrine Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Metacrine's Net Margin for the fiscal year that ended in Dec. 2021 is calculated as

Net Margin	=	Net Income (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-62.207	/	0
	=	%

Metacrine's Net Margin for the quarter that ended in Sep. 2022 is calculated as

Net Margin	=	Net Income (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	-5.521	/	0
	=	%

Metacrine (OTCPK:MTCR) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Metacrine Net Margin % Related Terms

Thank you for viewing the detailed overview of Metacrine's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Metacrine (Metacrine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metacrine Inc (OTCPK:MTCR) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3985 Sorrento Valley Boulevard, Suite C, San Diego, CA, USA, 92121

Website

https://www.metacrine.com

Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.

Executives

Michael York	officer: Chief Business Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Preston Klassen	director, officer: President & CEO	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Braden Michael Leonard	10 percent owner	156 S. FIRST STREET, ZIONSVILLE IN 46077
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett	10 percent owner
Scott D Sandell	10 percent owner
Venbio Global Strategic Fund, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Hubert C Chen	officer: Chief Medical Officer	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Julia C. Owens	director	C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451